Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions remain about long-term growth amid rising competition and the challenges of integrating a patient-focused, tech-heavy business.
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
Abbott and Medtronic — typically regarded as competitors — have recently joined forces. The two companies teamed up to collaborate on a continuous glucose monitoring system that combines Abbott’s FreeStyle Libre technology with Medtronic’s automated insulin delivery system.
Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers.
Abbott earned FDA approval for its dissolving stent designed to unclog arteries below the knee. This marks the first time the FDA has approved a stent or drug-coated balloon to help arteries stay open below the knee.
This year's J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
Abbott's new leadless pacemaker system has become commercially available and has begun being implanted in people at hospitals across the nation. Most people who need a pacemaker require pacing in two chambers of the heart, and the dual-chamber technology in Abbott's new system allows these patients to have a leadless pacemaker.
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.
Traditional fertility benefit practices — like dollar cap benefits and step therapy — are creating inequities in treatment, said Ann Gaines, senior vice president of business development at Progyny. Gaines made these comments Wednesday during the Midwest Business Group on Health conference in Chicago.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.
A look at how tapping real world evidence from medical devices and patients could be a game changer, improving patient-clinician communication, supporting earlier interventions and helping patients manage their condition.
Innovative approaches to real world evidence collection present opportunities for medical device companies to improve patient outcomes. But success will depend on improving the way medtech companies integrate digital health. Executives from Abbott, Smith & Nephew, AliveCor and Huma weigh in on these issues.
It is the first LVAD trial to examine five-year outcomes and surpasses a previous Abbott study on HeartMate 3, which recorded a survival time of two years. The device was found to reduce morbidity and mortality, largely because of fewer deaths by stroke, clotting and bleeding.
The nonprofit Digital Medicine Society is partnering with the likes of Google and the FDA to develop a free resource designed to help digital health startups navigate the regulatory process.